Update on Vaccinating the Patient With Inflammatory Bowel Disease
- 44 Downloads
Purpose of review
Patients with inflammatory bowel disease (IBD) are at increased risk of infectious diseases independent of their immunosuppression status, and yet, studies suggest that this population is not receiving standard vaccinations at the same rate as the general population. This review seeks to understand why IBD patients may not be receiving recommended immunizations and to provide guidelines on vaccinating this vulnerable population.
Inactive vaccines are recommended for patients with IBD regardless of immunosuppression status due to the increased risk for many vaccine-preventable illnesses. Certain live vaccines can be administered to the immunocompromised patient with IBD. Additionally, many patients with IBD will be immunosuppressed some time in their disease course, further increasing their risk for infection. Despite this understanding, patients with IBD have poor vaccination rates. Inadequate knowledge, limited time with patients, and lack of consensus as to who is responsible for identifying and administering vaccinations are some of the most important barriers to vaccinating the patient with IBD.
In this review, we discuss guidelines for vaccinating both the immunocompetent and immunosuppressed patient with IBD as well as provide vaccine-specific recommendations. The evidence suggests that patients with IBD are not receiving recommended vaccinations because of misconceptions on the part of patients as well as a paucity of knowledge by their health care team. Educational programs can be successfully implemented to increase knowledge about appropriate vaccinations and can ultimately increase vaccine uptake among patients with IBD. In the end, gastroenterologists and primary care physicians must work together with their patients with IBD to ensure that recommended vaccinations are administered.
KeywordsInflammatory bowel disease Immunocompromised Preventative health Vaccination PPSV23 PCV 13 Hepatitis A Hepatitis B Varicella Zoster HPV Travel
Compliance with ethical standards
Conflict of Interest
Francis Farraye reports personal fees from Braintree Labs, Ferring, Janssen, and Merck and personal fees from Pfizer, Takeda, Lilly, Mesoblast, Protagonist, Theravance, and Innovation Pharmaceuticals, outside the submitted work. Jennifer Coukos declares no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 3.• Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112(2):241–58 These guidelines by the ACG address the safety and appropriate timing of vaccinations in IBD patients. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system is used to evaluate the strength of each recommendation.CrossRefGoogle Scholar
- 6.• Reich J, Wasan S, Farraye FA. Vaccinating patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2016;12(9):540–6 In addition to outlining appropriate vaccinations, this article discusses strategies for improving vaccination rates among patients with IBD.Google Scholar
- 8.• Greveson K, Shepherd T, Mulligan JP, et al. Travel health and pretravel preparation in the patient with inflammatory bowel disease. Frontline Gastroenterol. 2016;7(1):60–5 This study showed that only a minority of patients with IBD seek pretravel advice and many providers do not feel comfortable providing this advice. A majority of clinicians would refer to a specialty clinic regardless of their confidence level. This article suggests that there still exists a need for greater education of patients with IBD prior to foreign travel.CrossRefGoogle Scholar
- 11.• Gurvits GE, Lan G, Tan A, Weissman A. Vaccination practices in patients with inflammatory bowel disease among general internal medicine physicians in the USA. Postgrad Med J. 2017;93(1100):333–7 This study demonstrates that primary care physicians have a poor understanding and comfort in regards to appropriate vaccinations for patients with IBD.CrossRefGoogle Scholar
- 12.Christensen KR, Steenholdt C, Buhl SS, Ainsworth MA, Thomsen OØ, Brynskov J. Systematic information to health-care professionals about vaccination guidelines improves adherence in patients with inflammatory bowel disease in anti-TNFα therapy. Am J Gastroenterol. 2015;110(11):1526–32.CrossRefGoogle Scholar
- 13.Reich JS, Miller HL, Wasan SK, Noronha A, Ardagna E, Sullivan K, et al. Influenza and pneumococcal vaccination rates in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2015;11(6):396–401.Google Scholar
- 17.• Tinsley A, Navabi S, Williams ED, et al. Increased risk of influenza and influenza-related complications among 140,480 patients with inflammatory bowel disease. Inflamm Bowel Dis. 2018; https://doi.org/10.1093/ibd/izy243 This is the first study designed to evaluate the incidence and severity of influenza in patients with IBD.
- 18.• Grohskopf LA, Sokolow LZ, Fry AM, et al. Update: ACIP recommendations for the use of quadrivalent live attenuated influenza vaccine (LAIV4)—United States, 2018–19 influenza season. MMWR Morb Mortal Wkly Rep. 2018;67:643–5 The updated ACIP guideline states that despite changing recommendation over the past few years, the live attenuated influenza vaccine (LAIV4) is an effective option for flu protection during the 2018–2019 season.CrossRefGoogle Scholar
- 20.• DeBruyn J, Fonseca K, Ghosh S, et al. Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomized trial. Inflamm Bowel Dis. 2016;22(3):638–47 Response to influenza vaccine is reduced in patients on infliximab. However, this study demonstrated that the timing of vaccine relative to infliximab infusion did not affect the achievement of serologic protection.CrossRefGoogle Scholar
- 22.Matsumoto H, Ohfuji S, Watanabe K, Yamagami H, Fukushima W, Maeda K, et al. Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial. J Gastroenterol. 2015;50(8):876–86.CrossRefGoogle Scholar
- 32.• Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination—updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2016;65:1405–8 The ACIP guidelines continue to recommend a 3-dose vaccine series for HPV if the vaccine is given at ages 15 through 26 years and for immunocompromised patients. However, the updated guidelines now support a 2-dose series if the vaccine is given at ages 9 through 14 years.CrossRefGoogle Scholar
- 41.• Jiang HY, Wang SY, Deng M, et al. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis. Vaccine. 2017;35(20):2633–41 This meta-analysis demonstrated poor serological response to hepatitis B vaccine in patients with IBD and provided several predictive variables for level of immune response.CrossRefGoogle Scholar
- 44.• Schillie S, Harris A, Link-Gelles R, et al. Recommendations of the advisory committee on immunization practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep. 2018;67(15):455–8 In July 2017, the FDA approved a new 2-dose hepatitis B vaccine (Heplisav-B, Dynavax) which can be given over one month compared to the 3-dose series over 6 months required for the older hepatitis B vaccines.CrossRefGoogle Scholar
- 51.• Caldera F, Saha S, Wald A, et al. Lower sustained diphtheria and pertussis antibody concentrations in inflammatory bowel disease patients. Dig Dis Sci. 2018;63(6):1532–40 This study is first to evaluate sustained protection against diphtheria and pertussis in patients with IBD.CrossRefGoogle Scholar
- 55.Khan N, Patel D, Trivedi C, et al. Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: A nationwide cohort study. Clin Gastroenterol Hepatol 2018. https://doi.org/10.1016/j.cgh.2017.12.052
- 56.• Yun H, Yang S, Chen L, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol. 2016;68(9):2328–37 This study found that younger patients with IBD have higher rates of shingles compared to older, healthy controls.CrossRefGoogle Scholar
- 57.• Dooling KL, Guo A, Patel M, et al. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wklyl Rep. 2018;67:103–8 The updates ACIP guidelines include the use of the recombinant zoster vaccine (Shingrix) that was approved in October 2017. This recombinant vaccine can be used in immunosuppressed patients unlike the live vaccine (Zostavax) which is contraindicated in patients on high level immunosuppression.CrossRefGoogle Scholar
- 59.• Wasan SK, Zullow S, Berg A, et al. Herpes zoster vaccine response in inflammatory bowel disease patients on low-dose immunosuppression. Inflamm Bowel Dis. 2016;22(6):1391–6 This study demonstrated that while patients with IBD on low-dose immunosuppression have a reduced response to the herpes zoster vaccine, they are not at an increased risk for serious adverse events.CrossRefGoogle Scholar
- 62.• Cleveland NK, Rodriquez D, Wichman A, et al. Many inflammatory bowel disease patients are not immune to measles or pertussis. Dig Dis Sci. 2016;61(10):2972–6 This study was the first to assess measles immunity and the largest study to assess pertussis titers in patients with IBD. The results revealed that a significant number patients with IBD lack immunity to measles and pertussis.CrossRefGoogle Scholar
- 65.Cornerstones Health, Inc. IBD checklist for monitoring & prevention. Version 1.5. www.cornerstoneshealth.org/wp-content/uploads/2017/06/Monitoring-and-Prevention-3.10.2017.pdf. Revised March 10, 2017. Accessed August 12, 2018.
- 66.Crohn’s & Colitis Foundation. Health maintenance checklist for adult IBD patients. Version 3. http://www.crohnscolitisfoundation.org/science-and-professionals/programs-materials/health-maintenance-checklist.pdf. Revised January 2018. Accessed August 12, 2018.
- 73.Apte M, Reich J, Zahorian T, Farraye FA. Improving vaccination rates for IBD patients through the use of local pharmacies. Inflamm Bowel Dis. 2018. https://doi.org/10.1093/ibd/izy209